April 2012 in “Journal of the American Academy of Dermatology” Clofazimine effectively treated ashy dermatosis in a patient.
28 citations
,
December 2001 in “European Journal of Pharmacology” M50054 may help treat hepatitis and hair loss from chemotherapy.
54 citations
,
April 2020 in “Experimental & Molecular Medicine” Cox-2 significantly contributes to the development and progression of skin and esophageal cancers.
1 citations
,
August 2024 in “Indian Dermatology Online Journal” Bicalutamide may effectively treat female pattern hair loss with minimal side effects.
September 2023 in “Journal of the American Academy of Dermatology” The cosmetic product improved melasma and skin quality without causing irritation.
March 2025 in “International Journal of Trichology” Low-dose oral minoxidil is safe for the heart.
1 citations
,
October 2023 in “BMC oral health” Two patients treated with TAC for mouth fibrosis improved but developed Cushing's Syndrome symptoms.
January 2025 in “International Journal of Pharmaceutical Research and Applications” Hibiscus mucilage is an effective gelling agent for diclofenac diethylamine gel.
25 citations
,
January 2021 in “Journal of drugs in dermatology” Sonidegib and vismodegib are similarly effective for advanced basal cell carcinoma, but sonidegib might have a slightly better safety profile.
Abemaciclib can cause skin, hair, and nail problems, leading some patients to stop using it.
May 2024 in “News Digital Object Group” 74 citations
,
January 2011 in “Reproductive Biology and Endocrinology”
8 citations
,
March 2019 in “Drugs - Real World Outcomes” Healthcare claims databases can help monitor drug safety, but may report adverse events differently than direct surveillance.
3 citations
,
May 2025 in “Frontiers in Pharmacology” Vismodegib can cause muscle spasms, taste changes, hair loss, fatigue, weight loss, and possibly new issues like skin cancer, dehydration, and swallowing problems, needing close monitoring.
January 2026 in “Frontiers in Pharmacology” Wedelolactone may help treat inflammation, infections, cancer, bone loss, and organ damage.
1 citations
,
October 2025 in “Scientific Reports” Sonidegib and vismodegib have different side effects and reporting patterns.
39 citations
,
September 2015 in “Clinical Therapeutics” Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.
10 citations
,
March 2022 in “Healthcare” Mineralocorticoid receptor antagonist therapy does not significantly reduce mortality in COVID-19 patients.
64 citations
,
December 2003 in “Veterinary Dermatology” Triamcinolone is more effective and safer for treating feline pemphigus foliaceus than prednisone.
September 2023 in “Journal of The American Academy of Dermatology” Low-dose oral minoxidil may be effective for hair loss treatment.
Thiolated cyclodextrin-based nanoparticles effectively deliver Minoxidil for scalp treatment without causing skin irritation.
3 citations
,
November 2017 in “International Journal of Pharmacy and Pharmaceutical Sciences”
June 2023 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Bicalutamide mesotherapy improved hair density in women with hair loss and was well received.
February 2024 in “Journal of Molecular Structure” The new minoxidil and salicylic acid hydrogel improves alopecia treatment.
155 citations
,
August 1991 in “Journal of The American Academy of Dermatology” Methotrexate treats various disorders by inhibiting DNA synthesis, but careful monitoring is needed to avoid toxicity and manage side effects.
3 citations
,
August 2022 in “JAAD case reports” A woman developed swelling in her body after taking low-dose oral minoxidil for hair loss, but it resolved after stopping the medication.
29 citations
,
October 2009 in “Pharmacology Biochemistry and Behavior” January 2017 in “Zenodo (CERN European Organization for Nuclear Research)” The minoxidil emulgel is feasible and may be more effective for treating male pattern baldness.
3 citations
,
March 2017 in “Regulatory toxicology and pharmacology” Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.